Skip to main content

February 2015 Vol 8, Special Issue: Payers' Perspectives in Oncology

Multiple Myeloma, Oncology
New Data on Ixazomib Maintenance Support Long-Term Oral Therapy in Patients with Myeloma
Kate Smith
Read More
Multiple Myeloma, Oncology
Novel Oral Proteasome Inhibitor Oprozomib Shows Promise in Myeloma
Read More
Multiple Myeloma, Oncology
Weekly Carfilzomib Safe and Effective
Kate Smith
Read More
Lymphoma
Immunotherapy with PD-1 Inhibitors the Newest Break­­through in Hodgkin Lymphoma
Wayne Kuznar
Read More
Multiple Myeloma, Oncology
Monoclonal Antibodies Poised to Be “Blockbusters” in Myeloma
Kate Smith
Read More
FDA Approvals
Recent FDA Approvals
Read More
Orphan Drug Expenditures in the United States Expected to Stabilize
Wayne Kuznar
Read More
Economic Value of Survival Gains for MDS Could Exceed $100 Billion
Chase Doyle
Read More
Once Off Patent, Imatinib Will Be the Most Cost-Effective Treatment for Newly Diagnosed CML
Wayne Kuznar
Read More
High Cancer Drug Prices Hurt Patients
Read More
Page 2 of 3
Results 11 - 20 of 26